New test has no added value in Lyme disease of the central nervous system Active Lyme disease of the central nervous system cannot be detected with an ELISpot test.
Lyme disease costs EUR 20 million annually The societal costs of Lyme disease have been determined for the Netherlands for the first time. The disease appears to cost nearly EUR 20 million each year.
Blood spot test extended as of 1 January 2017 to include two more disorders As of 1 January 2017, the disorders alpha and beta thalassaemia will be added to the neonatal blood spot (‘heel prick’) screening programme.
Assessment of health effects of alternative tobacco products To assess the effects on the health of users of alternative tobacco products, more knowledge is required about the composition of the product, the smoker’s behaviour (such as the amount of cigarett
Bacteria slightly more often resistant to last resort antibiotics Antimicrobial resistance is a global problem. In the Netherlands, some bacteria that can cause infections in people are more frequently resistant to antibiotics used as a last resort.
Lab tests alone not conclusive for diagnosis of Lyme disease Lyme disease can cause a variety of complaints in patients. Laboratory tests for the disease can support medical practitioners in making a diagnosis but are not necessarily conclusive.
More tobacco products, number of additives stable In 2014, the number of tobacco products on the Dutch market increased to 4212. This is a 5 percent increase compared to 2013.
European Antibiotic Awareness Day: the fight against antibiotics resistance Wednesday, 18 November is European Antibiotic Awareness Day. On this day, attention throughout Europe is requested for the responsible use of antibiotics in people and animals.
Newborn heel prick screening starts on St Eustatius and Saba On 26 October 2015, heel prick screening started for all newborns on St Eustatius and Saba.
CAESAR annual report 2014 The World Health Organization (WHO) published its first CAESAR annual report 2014.